Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of olanzapine + samidorphan (ALKS 3831) versus olanzapine + placebo in schizophrenia with alcohol use disorder
2014-001211-39Phase 2Completed
- Sponsor
- Alkermes
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia and alcohol use disorder (AUD) comparing Olanzapine + samidorphan (ALKS 3831) with Olanzapine + placebo (2 arms). Primary endpoint: Time to exacerbation of disease symptoms. Started Oct 2014; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophreniaalcohol use disorder (AUD)
Beyond the preview
Go deeper on 2014-001211-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001211-39.